| Patient | Arthur Ashe |
|---|---|
| Date of birth | 1943-07-10 |
| Identifiers | MRN HR-ML013-SYN-TD; SSN (made up) 000-13-6620 |
| Document date | 1989-07-13 |
| Author | Vivian Tolliver, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-month HIV and coronary disease review with depression screening. [S]
Mr. Ashe returns six months after his first visit. He has missed no doses. He has had no headache, weakness, rash, fever, or chest pain, and has not needed nitroglycerin. He is back to full-time writing and coaching. He gave a urine sample with this morning's blood tests. He answered the PHQ-9 with a score of 2 and has no thoughts of self-harm. He says that knowing his viral load is undetectable has eased his mind. [S]
| Element | Detail |
|---|---|
| Adherence | No missed doses |
| Work | Full-time writing and coaching |
| Mood | PHQ-9 2; item 9 scored 0 |
| Heart | No angina; nitroglycerin not used |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever; weight up 0.8 kg |
| Cardiovascular | Negative | No chest pain or palpitations |
| Neurological | Negative | No headache, seizure, or weakness |
| Psychiatric | Negative | Mood good; PHQ-9 score 2; no thoughts of self-harm |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg, one tablet by mouth once daily; take two hours before or six hours after antacids, calcium, iron, or magnesium | One tablet by mouth once daily | Oral route | 1988-09-25 | active | S |
| Pyrimethamine 25 mg oral tablet, 200 mg once, then three tablets (75 mg) by mouth daily for six weeks; course completed before intake | Three tablets by mouth daily after a 200 mg loading dose | Oral route | 1988-09-11 to 1988-10-23 | completed | S |
| Sulfadiazine 500 mg oral tablet, three tablets (1500 mg) by mouth every 6 hours for six weeks; course completed before intake | Three tablets by mouth every 6 hours | Oral route | 1988-09-11 to 1988-10-23 | completed | S |
| Leucovorin 10 mg oral tablet, two tablets (20 mg) by mouth daily with pyrimethamine; course completed before intake | Two tablets by mouth daily | Oral route | 1988-09-11 to 1988-10-23 | completed | S |
| Sulfamethoxazole 800 mg and trimethoprim 160 mg (double strength), one tablet by mouth twice daily | One tablet by mouth twice daily | Oral route | 1988-10-23 to 1989-10-19 | completed | S |
| Aspirin 81 mg delayed-release oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1979-07-31 | active | S |
| Atorvastatin 80 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1979-08-01 | active | S |
| Ezetimibe 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1989-01-12 | active | S |
| Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue every 5 minutes as needed for chest pain, up to 3 tablets; call 911 if pain is not better 5 minutes after the first tablet | One tablet under the tongue every 5 minutes as needed for chest pain, up to 3 doses | Sublingual route | 1979-08-01 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1989-07-13 | Body height | 185 | cm | S |
| 1989-07-13 | Body weight | 74.6 | kg | S |
| 1989-07-13 | Body mass index (BMI) [Ratio] | 21.8 | kg/m2 | S |
| 1989-07-13 | Systolic blood pressure | 118 | mm[Hg] | S |
| 1989-07-13 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 1989-07-13 | Heart rate | 66 | /min | S |
| 1989-07-13 | Respiratory rate | 14 | /min | S |
| 1989-07-13 | Body temperature | 36.6 | Cel | S |
| 1989-07-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1989-07-13 | HIV 1 RNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection | 0 | {copies}/mL | Below 20 copies/mL (limit of quantification); 0 means HIV-1 RNA not detected | Normal | S |
| 1989-07-13 | CD3+CD4+ (T4 helper) cells [#/volume] in Blood | 262 | /uL | 500-1500 /uL | Low | S |
| 1989-07-13 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 1989-07-13 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1989-07-13 | Creatinine [Mass/volume] in Serum or Plasma | 1.14 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 1989-07-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1984)/1.73 sq M | 80 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1989-07-13 | Glucose [Mass/volume] in Serum or Plasma | 93 | mg/dL | 70-99 mg/dL | Normal | S |
| 1989-07-13 | Albumin/Creatinine [Mass Ratio] in Urine | 12 | mg/g | <=29 mg/g | Normal | S |
| 1989-07-13 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | {score} | S |
Vital signs recorded on 1989-07-13; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 74.6 kg, blood pressure 118/72 |
| Cardiovascular | Regular rhythm; no murmur; no edema |
| Neurological | No focal deficit |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| HIV infection, diagnosed about four months before intake with a CD4 count of 58 cells/uL and cerebral toxoplasmosis (an AIDS-defining illness); on antiretroviral therapy since; synthetic modern episode linked to the documented transfusion-acquired infection | active | confirmed | B20 | S — Synthetic modern coding of the documented HIV infection and AIDS diagnosis; B20 stays the code after an AIDS-defining illness, however well the infection is controlled. |
| Cerebral toxoplasmosis, single left-sided lesion with right-hand weakness, diagnosed by stereotactic biopsy; six weeks of acute treatment completed; weakness recovered; on maintenance therapy | active | confirmed | B58.2 | S — Synthetic modern coding of the documented 1988 toxoplasmosis; the modern diagnosis was by biopsy rather than removal of the mass. |
| Coronary artery disease after two bypass operations (quadruple, then double), no angina; synthetic modern episode linked to the documented 1942 and 1946 operations | active | confirmed | I25.10 | S — Synthetic modern diagnosis; the history remains D. |
| Old myocardial infarction at age 36 | active | confirmed | I25.2 | S — Synthetic coded history of the documented 1979 heart attack. |
| Hyperlipidemia, on high-intensity statin | active | confirmed | E78.5 | S — Synthetic diagnosis; no cholesterol value from his lifetime is used. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | HIV-1 viral load | 4 to 8 weeks after starting ART, every 4 to 8 weeks until suppressed, then every 3 months | Completed today | Not detected (below 20 copies/mL), the second undetectable result |
| Laboratory | CD4 count | Every 3 months while below 200 and on prophylaxis; every 3 to 6 months in the first 2 years of ART | Completed today | 262 cells/uL |
| Medication safety | ART adherence and drug-interaction review (antacids, calcium, iron, new medicines) | Every visit | Completed today | No missed doses; no interacting medicines |
| Laboratory | Complete blood count | Every 3 months on trimethoprim-sulfamethoxazole; every 3 to 6 months on ART | Up to date | Normal three months ago; next at nine months |
| Laboratory | Potassium, creatinine, and eGFR | 1 to 4 weeks after starting trimethoprim-sulfamethoxazole, then every 3 to 6 months | Completed today | Potassium 4.6 mmol/L, creatinine 1.14 mg/dL, eGFR 80 |
| Laboratory | Urine albumin-to-creatinine ratio on tenofovir | At the start of tenofovir and yearly | Completed today | Albumin-to-creatinine ratio 12 mg/g, normal; collected late after the deviations recorded at four weeks and three months; no harm resulted |
| Laboratory | ALT | Every 6 months on ART; with symptoms on a statin | Up to date | ALT 27 U/L three months ago |
| Medication safety | Toxoplasma maintenance therapy and stopping criteria | Continue until CD4 above 200 for more than 6 months on ART with a suppressed viral load | Completed today | CD4 above 200 for three months; continue to nine months |
| Medication safety | Pneumocystis prophylaxis | While CD4 below 200; stop after more than 3 months above 200 | Completed today | CD4 above 200 for three months; covered by the maintenance dose, which continues |
| Examination | Neurological check: headache, seizure, weakness, and right-hand strength | Every visit | Completed today | No symptoms |
| Self-management | Recombinant zoster vaccine | Two doses 2 to 6 months apart, from age 18 with HIV | Due | Dose 2 at the preventive visit next month |
| Self-management | Psychosocial support, disclosure on his terms, and U=U counseling | Every visit | Completed today | Reassured by his undetectable results; disclosure remains his decision |
| Survey | Depression screen (PHQ-9 or PHQ-2) | At intake, at six months, and yearly | Completed today | PHQ-9 2, with item 9 scored 0 |
| Examination | Blood pressure (goal below 130/80) | Every visit | Completed today | 118/72 mmHg |
| Examination | Weight, BMI, and physical activity | Every visit | Completed today | 74.6 kg, BMI 21.8; full-time work and exercise three times a week |
| Self-management | Tobacco use | Every visit | Completed today | Never used tobacco |
| Medication safety | Coronary medicine adherence: aspirin 81 mg, high-intensity statin, ezetimibe | Every visit | Completed today | Taking all three |
| Self-management | Angina review and chest-pain plan | Every visit | Completed today | No angina |
| Laboratory | Lipid panel | 4 to 12 weeks after a change, then every 3 to 12 months; yearly when stable | Up to date | LDL 52 mg/dL three months ago; yearly from now on |
| Imaging | Stress testing, coronary imaging, or echocardiography | Only with new or worsening symptoms; routine surveillance not recommended | Not indicated | No symptoms |
Goal progress:
Guideline basis: Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV (current online edition); Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV: Toxoplasma gondii encephalitis and Pneumocystis pneumonia sections (current online edition); Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society-USA Panel (2024); Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America (2020); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); Adult Immunization Schedule by Medical Condition and Other Indication (2026); Depression and Suicide Risk in Adults: Screening (2023); CMID: Clinical Monitoring Intelligence Database, ischemic heart disease and hyperlipidemia monographs (2026)
Follow-up: Preventive visit next month with the second zoster dose. Nine-month HIV review with blood tests. Next scheduled visit 1989-08-17: periodic adult preventive visit. [S]